Equity Insider News Commentary
Issued on behalf of Oncolytics Biotech Inc.
VANCOUVER, BC, May 23, 2025 /CNW/ -- Equity Insider News Commentary – With early onset cancer rates on the rise and funding being cut to NIH, the future for cancer patients is increasingly being shaped not by public institutions, but by the breakthroughs emerging from the private sector. For investors watching the next wave of oncology breakthroughs, companies like Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC.TO), Akoya Biosciences, Inc. (NASDAQ:AKYA), Quanterix Corporation (NASDAQ:QTRX), TScan Therapeutics, Inc. (NASDAQ:TCRX), and Arcellx, Inc. (NASDAQ:ACLX) are increasingly standing out.
Read more at newswire.caThis article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
/Nvidia%20logo%20and%20sign%20on%20headquarters%20by%20Michael%20Vi%20via%20Shutterstock.jpg)
/Goldman%20Sachs%20Group%2C%20Inc_%20logo%20sign-by%20Poetra_RH%20via%20Shutterstock.jpg)
/A%20SoFi%20logo%20on%20an%20office%20building%20by%20Tada%20Images%20via%20Shutterstock.jpg)
/AI%20(artificial%20intelligence)/3D%20Graphics%20Concept%20Big%20Data%20Center%20by%20Gorodenkoff%20via%20Shutterstock.jpg)